Abstract
Heart failure (HF) represents a complex multifactorial syndrome, characterized by crucial structural and functional abnormalities of the myocardium. Matrix metalloproteinases are associated with left ventricular dysfunction, adverse left ventricular remodelling and prognosis after acute myocardial infarction. There is a strong association between oxidative stress and MMPs in the pathophysiology of HF. As MMPs are strongly associated to the pathogenesis and pathophysiology of HF, several agents have been proposed as potential modulators of these molecules. Classical agents such as statins, angiotensin converting enzyme inhibitors (ACEIS) and beta-blockers and a variety of novel agents have been implicated in the pathogenesis and progression of heart failure via the matrix metalloproteinases pathway and consist of possible future therapeutic targets.
Keywords: Clinical implications, dysfunction, heart failure, left ventricle remodeling, matrix metalloproteinases, multifactorial syndrome, oxidative stress, crucial structural, myocardium, ventricular dysfunction, pathophysiology, ventricular remodelling, therapeutic targets, enzyme inhibitors
Current Topics in Medicinal Chemistry
Title:Matrix Metallopropteinases in Heart Failure
Volume: 12 Issue: 10
Author(s): Dimitris Tousoulis, Anna-Maria Kampoli, Nikolaos Papageorgiou, Charalambos Antoniades, Gerasimos Siasos, George Latsios, Eleftherios Tsiamis and Christodoulos Stefanadis
Affiliation:
Keywords: Clinical implications, dysfunction, heart failure, left ventricle remodeling, matrix metalloproteinases, multifactorial syndrome, oxidative stress, crucial structural, myocardium, ventricular dysfunction, pathophysiology, ventricular remodelling, therapeutic targets, enzyme inhibitors
Abstract: Heart failure (HF) represents a complex multifactorial syndrome, characterized by crucial structural and functional abnormalities of the myocardium. Matrix metalloproteinases are associated with left ventricular dysfunction, adverse left ventricular remodelling and prognosis after acute myocardial infarction. There is a strong association between oxidative stress and MMPs in the pathophysiology of HF. As MMPs are strongly associated to the pathogenesis and pathophysiology of HF, several agents have been proposed as potential modulators of these molecules. Classical agents such as statins, angiotensin converting enzyme inhibitors (ACEIS) and beta-blockers and a variety of novel agents have been implicated in the pathogenesis and progression of heart failure via the matrix metalloproteinases pathway and consist of possible future therapeutic targets.
Export Options
About this article
Cite this article as:
Tousoulis Dimitris, Kampoli Anna-Maria, Papageorgiou Nikolaos, Antoniades Charalambos, Siasos Gerasimos, Latsios George, Tsiamis Eleftherios and Stefanadis Christodoulos, Matrix Metallopropteinases in Heart Failure, Current Topics in Medicinal Chemistry 2012; 12 (10) . https://dx.doi.org/10.2174/1568026611208011181
DOI https://dx.doi.org/10.2174/1568026611208011181 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The First Line of Defense Against Cardiac Hypertrophy
Current Molecular Medicine Current Research on Opioid Receptor Function
Current Drug Targets Circulatory Syndrome: An Evolution of the Metabolic Syndrome Concept!
Current Cardiology Reviews Imaging Epigenetics in Alzheimer’s Disease
Current Pharmaceutical Design Opiates as Antidepressants
Current Pharmaceutical Design Microvascular Endothelial Dysfunction in Obesity and Hypertension
Current Pharmaceutical Design Recent Patents on Biomedical Applications for the Treatment of Atherosclerosis
Recent Patents on Regenerative Medicine Possible Neuroprotective Strategies for Huntingtons Disease
Current Neuropharmacology Imaging of Visceral Adipose Tissue: An Emerging Diagnostic Tool and Therapeutic Target
Current Drug Targets - Cardiovascular & Hematological Disorders Endothelial Dysfunction in the Hypertensive State: Mechanisms of Hypertensive Cardiovascular Complications
Current Hypertension Reviews SALL4: Engine of Cell Stemness
Current Gene Therapy Conduction Disorders: The Value of Surface ECG
Current Cardiology Reviews Hypertension in Children with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Current Hypertension Reviews Vascular Calcification and Subendocardial Ischemia in Hemodialysis Patients: A New Morpho-Functional Score to Assess Cardiovascular Risk: the Solofra Score
Current Hypertension Reviews Effect of Dipeptidyl Peptidase-4 Inhibitors on Plasma Adiponectin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Medicinal Chemistry Long-term Outcomes of Mitral Valve Repair Versus Replacement for Degenerative Disease: A Systematic Review
Current Cardiology Reviews Resveratrol: A Therapeutic Promise for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery The Interaction Between Gender and Diabetes Mellitus in the Coronary Heart Disease Risk
Current Pharmaceutical Design The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design The Pyruvate Dehydrogenase Complex as a Target for Gene Therapy
Current Gene Therapy